Development and Evaluation of Artemether-loaded Microspheres Delivery System for Oral Application in Malaria Treatment doi.org/10.26538/tjnpr/v5i11.23
Main Article Content
Abstract
The application of artemether for the treatment of malaria is limited by its poor solubility leading to low bioavailability. The current study formulated sustained-release artemether mucoadhesive microspheres for oral delivery to prolong oral artemether delivery and improve the low bioavailability. Microspheres were formulated with mixtures of Eudragit®RS100 and Eudragit®RL100 in ratios of; 1:1 (A1), 1:3 (A2), and 3:1 (A3) by solvent evaporation techniques. The percentage yield, particle sizes, encapsulation efficiency (EE%), flow property, differential scanning calorimetry (DSC), Scanning electron microscopy (SEM), bioadhesion study, in vitro and in vivo studies of the microspheres were evaluated and characterized. Results show that microspheres exhibited an overall high percentage yield of up to 98%. Particle sizes were between 29.40 ± 0.18 - 41.42 ± 0.12 µm. EE (%) obtained were 93.0, 94.5, and 95.0% for A1, A2, and A3, respectively. Flow characteristics indicated that the microspheres had good flowability. Thermal analysis of the drug and the microspheres showed sharp melting peaks which indicated that the drug was pure and crystalline. Morphological characteristics exhibited fairly spherical in shape. Bioadhesion properties depicted that microspheres exhibited good mucoadhesion properties on the bovine ileum. Drug release in simulated gastric fluid (SGF) ranged from 2.24 to 19.3% as compared to 60.43-83.31% in simulated intestinal fluid (SIF). The decreased in parasitemia levels are 91.78 ± 0.53%, 87.35 ± 0.23%, and 81.82 ± 0.31% for A3, A2 and A1, respectively. This method shows a promising result for possible delivery of artemether with improved sustained release activity.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
World Health Organization. Guidelines for the Treatment of malaria (1st ed) World Malaria Report WHO/HTM/MAL.
; 1108. Cited by 3019 – Geneva: 2015. Availablerfrom: (http://www.who.int/entity/malaria/publications/atoz/97892
/en/index.html).
Dellicour S, Tatem AJ, Guerra CA, Snow RW, Kuile FO. “Quantifying the Number of Pregnancies at Risk of Malaria
in 2007: A Demographic Study,” PLoS Med. 2010; 7(1):e1000221.
White NJ. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Transact Roy Soc Trop Med Hyg. 1994; 88(1):S41–S43.
Nosten F and White NJ. Artemisinin-based combination treatment of falciparum malaria, The Am J Trop Med Hyg.
; 77:181-192.
Afonso A, Hunt P, Cheesman S, Alves AC, Cunha CV, Rosário VD, Cravo P. Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes ATP 6 (encoding the sarcoplasmic and endoplasmic
reticulum Ca2+ ATPase), TCTP, MDR1, and CG 10, Antim Agents Chem. 2006; 50(2):480-488.
Ugwu CE, Obitte NC, Onunkwo GC. Improvement on the oral bioavailability of artemether by a designed supersaturable self-emulsifying drug delivery system as a potential for prevention of in vivo drug crystallization. W J
Pharm Res. 2016; 5(7):87-103.
Ugwu CE, Ugwu DC, Attama AA. Formulation and in vitro Characterization of Amorphous Based-Solid Dispersion of
An Antimalarial Drug. Int J Pharm Sci Rev Res. 2019; 58(2):1-9.
Santos-Magalhaes NS and Mosqueira VCF. Nanotechnology Applied to the treatment of malaria. Adv Drug Del Rev. 2010; 62(4-5):560-575.
Sosnik A and Amiji M. Nanotechnology solutions for infectious diseases in developing nations. Adv Drug Del Rev. 2010; 62(4-5):375-377.
Akhgari A, Afrasiabi-Garekani H, Sadeghi F, Azimaie M.Statistical optimization of indomethacin pellets coated with
pH-dependent methacrylic polymers for possible colonic drug delivery. Int J Pharm. 2005; 305(1-2):22-30.
Obitte NC, Chime SA, Attama AA, Odo JI, Brown SA. Evaluation of the pharmacodynamic properties of indomethacin-loaded lipospheres. Inter Res J Pharm Pharmacol. 2013; 3(5):77-84.
Momoh AM, Ugwu CE, Nafiu A, Kenechukwu CF, Adedokun OM, Mohammed U, Barikisu A, Oyeniyi YJ, Kenneth CO, Attama AA, Emmanuel CI, David DD. Mucin-grafted polyethylene glycol microparticles enable oral insulin delivery for improving diabetic treatment. Appl Sci. 2020; 10:2649
Aulton ME. Pharmaceutics; The Science of Dosage Form Design. (3rd Ed). Churchill Living Stone, Edinburgh. 2007; 197-210p.
Ugwu CE, Chime SA, Isha CE. Evaluation of excipient potentials of alpha-cellulose extracted from rice husk in metronidazole compressed tablets: Colon targeted drug delivery and in vitro characterizations. J Chem Pharm Res.
; 11(2):92-116.
Higuchi T. Mechanism of sustained-action medication: Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963; 52(12):1145-1149.
Korsmeyer RG, Doelker E, Buri P, Gunny R, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983; 15(1):25-35.
Peters W, Robinson BL, Torey G, Rossier JC, Jefford CW. The chemotherapy of rodent malaria 1. The activities of some synthetic I, 2, 4-trioxanes against chloroquinesensitive and chloroquine resistant parasite, part 3: observations Fenozan-5 of a di-fluorated 3, 3-Spirocyclopentane1, 2, 4-trioxane. Ann Trop Med Paras. 1993; 87:111-123.
European Community Council Directive on the ethics of experiments involving laboratory animals (86/609/EEC), November 24, 1986. Cited January, 2012. Available from:
https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:en:PDF
Chadha R, Gupta S, Pathak N. Artesunate-loaded chitosan/ lecithin nanoparticles: preparation, characterization, and in vivo studies. Drug Dev Ind Pharm. 2012; 38(12):1538-1546.
Agubata CO, Nzekwe IT, Attama AA, Mueller-Goymannv CC, Onunkwo GC, Pharmaceutical nanotechnology Formulation, characterization and anti-malarial activity of homolipid-based artemether microparticles. Int J Pharm.
; 478:202-222.
Kenechukwu FC, Attama AA, Ibezim EC, Nnamani PO, Umeyor CE, Uronnachi EM, Gugu TH, Momoh MA, Ofokansi KC, Akpa PA. Surface-modified mucoadhesive microgels as a controlled release system for miconazole nitrate to improve localized treatment of vulvovaginal Candidiasis. Eur J Pharm Sci. 2018; 111:358-375.
Kibbe AH. Polymethacrylates. Handbook of pharmaceutical excipients. (3rd ed). American Pharmaceutical association, Washington, USA and Pharmaceutical Press, London UK, 2000; p 401-406.Aijaz A, Sheikh KR, Biyani, NM. Gawai, Fauziya F, Sonali DI. Formulation, Characterization and in vitro evaluation of mucoadhesive microspheres of clarithromycin and omeprazole. Res J Pharm Technol.2011;4(11):1721-1724.